ClinicalTrials.gg
RecruitingNCT06794541Updated May 5, 2026

A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)

A Phase 2 interventional study of IV Eravacycline 2mg/kg and IV Eravacycline 1.5mg/kg in Complicated Intra-abdominal Infections (cIAI), sponsored by Tetraphase Pharmaceuticals, Inc. Recruiting at 5 sites in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Tetraphase Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Intraabdominal Infections with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Intraabdominal Infections · United States.

Planned enrollment
21st of 24
35 · median 144
Started
2025
the only one that year
Phase 2
9 of 29
1 open now
Registered
28th of 29
by date

Among the 29 studies in Intraabdominal Infections with a site in United States, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2025, is one of 9 in phase 2, and was the 28th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

3 of the 29 studies in Intraabdominal Infections with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intraabdominal Infections with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 trial to assess safety, tolerability, and pharmacokinetics of eravacycline in pediatric patients aged 8 to \<18 years with cIAI.

03

Conditions studied

  • Complicated Intra-abdominal Infections (cIAI)

Keywords

  • Complicated Intra-abdominal Infections
  • cIAI
  • eravacycline
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children from 8 to \<18 years of age (as of the day of the [and assent, if applicable] is obtained), hospitalized for cIAI with one of the following diagnoses:

    1. Intra-abdominal abscess (including hepatic and splenic abscesses).
    2. Gastric or intestinal perforation associated with diffuse peritonitis.
    3. Peritonitis: diffuse infection of the peritoneum (but not spontaneous bacterial peritonitis associated with cirrhosis and chronic ascites).
    4. Appendicitis with perforation, peritonitis, or abscess (complicated appendicitis).
    5. Cholecystitis with perforation or abscess.
  2. Patient has one or more systemic signs or symptoms that accompany cIAI, such as fever, leukocytosis, hypotension, abdominal pain, nausea/vomiting, anorexia, abdominal mass on clinical examination, or altered mental status
  3. Written informed consent from parent(s) or other legally authorized representative(s) and assent (according to local requirements).
  4. In the investigator's opinion, the patient will require hospitalization for at least 4 days.
  5. The patient must require hospitalization initially and antibacterial therapy for 4 to 14 days in addition to surgical intervention for the treatment of the current cIAI based on the judgment of the investigator.
  6. The patient has sufficient intravascular access (peripheral or central) to receive eravacycline.
  7. The patient meets either (A or B) of the following criteria:

    1. Pre-operative enrollment:

      • i. Has a sonogram or radiographic imaging result consistent with the diagnosis of cIAI, and
      • ii. Acute surgical or percutaneous intervention (open laparotomy, laparoscopic surgery, or percutaneous drainage of an abscess) is foreseen within 24 hours.

      OR

    2. Intra-operative/postoperative enrollment:

      • i. Visual confirmation of cIAI (presence of pus within the abdominal cavity), and
      • ii. Surgical intervention includes open laparotomy, laparoscopic surgery, or percutaneous draining of an abscess, and
      • iii. Intervention is considered adequate by the surgical team.

Exclusion criteria

Exclusion Criteria:

  1. Patient is considered by the investigator to be unlikely to survive the trial period, and/or has any rapidly progressing disease or immediately life-threatening illness.
  2. Patient's laboratory test results reveal or aspartate transaminase >5× (ULN).
  3. Patient's laboratory test results reveal total >2×ULN, unless isolated hyperbilirubinemia is directly related to the acute process.
  4. Patient requires peritoneal dialysis, hemodialysis, or hemofiltration at screening. Patient has an estimated (eGFR) \<50 mL/minute/1.73 m².
  5. Patient has previously received eravacycline or have enrolled previously in the current trial and been discontinued.
  6. Patient has evidence or history of a medical condition that may, in the opinion of the investigator, impair trial participation or pose a significant safety risk or diminish the patient's availability to undergo all trial procedures and assessments.
  7. Patient is likely to require more than 14 days of treatment with eravacycline, in the opinion of the investigator.
  8. Patient is currently participating in or has participated in an interventional clinical trial with an compound or device within 30 days or \<5 half-lives of the investigational compound (whichever is longer) prior to screening.
  9. Patient has condition, including acquired immune deficiency syndrome (AIDS), organ (including bone marrow) transplant recipients, and hematologic , or receiving immunosuppressive therapy, including cancer chemotherapy, medications for prevention of organ transplantation rejection, or chronic administration of systemic (defined as the systemic equivalent of ≥2 mg/kg total daily dose of prednisone for patients ≤20 kg, or >40 mg of prednisone per day for patients >20 kg, administered continuously for more than 14 days in the 30 days prior to the first dose of eravacycline.
  10. Patient has known or suspected inflammatory bowel disease.
  11. Patient has pancreatitis.
  12. Patient has systemic malignancy that required chemotherapy, immunotherapy, radiation therapy, or antineoplastic therapy within the previous 3 months.
  13. Patient has history of or allergic reaction to any tetracycline antibiotics.
  14. Patient has cIAI caused by a pathogen(s) resistant to eravacycline at screening.
  15. Patient has received antibacterial drug therapy for continuous duration of >72 hours immediately preceding screening unless they are considered treatment failures. Note: Treatment failure is defined as persistent fever and/or clinical symptoms or the development of a new intra-abdominal abscess after ≥72 hours of antibiotic therapy.
  16. Patient has received any tetracycline within 14 days of screening.
  17. Patient used cytochrome P450 (CYP) 3A inducers or inhibitors within 14 days of screening or is receiving or anticipated to need treatment with inducers or inhibitors during the treatment period. (The use of a single dose of a moderate or weak CYP3A inducer used within 14 days prior to screening is allowed)
  18. Patient is currently using or anticipates use of anticoagulant therapy during the treatment period.
  19. Patient is unable or unwilling, in the opinion of the investigator, to comply with the protocol.
  20. Patients who are known to be pregnant (positive pregnancy test) and/or breastfeeding at the time of screening.
  21. Sexually active patients of (those with menarche and/or thelarche) who are unwilling or unable to use an acceptable method of (at least 2 medically accepted, effective methods of birth control [e.g., condom, oral contraceptive, indwelling intrauterine device, hormonal implant/patch, injections, approved cervical ring]) or sexual abstinence during study treatment and for 14 days after the last dose of study drug.
  22. Patient has any other circumstance that, in the opinion of the investigator, precludes the patient's participation in the trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Eravacycline intravenous (IV) will be administered every 12 hours for participants 12 to \<18 years of age

    Drug: IV Eravacycline 1.5mg/kg

  • Experimental
    Cohort 2a

    Eravacycline IV will be administered every 12 hours for participants 10 to \<12 years of age

    Drug: IV Eravacycline 2mg/kg

  • Experimental
    Cohort 2b

    Eravacycline IV will be administered every 12 hours for participants aged 8 to \<10 years of age

    Drug: IV Eravacycline 2mg/kg

Interventions

  • DrugIV Eravacycline 2mg/kg

    Drug page: Eravacycline

    infused over a 60-minute period

  • DrugIV Eravacycline 1.5mg/kg

    Drug page: Eravacycline

    infused over a 60-minute period

06

What researchers measure

Primary outcomes

  1. Proportion of patients with Adverse Events (AEs) from the first dose of any amount of eravacycline

    Time frame: 28 days

  2. Change from baseline values over time in electrocardiogram (ECG) QT measurements

    Time frame: Day 28

  3. Change from baseline values over time in diastolic blood pressure

    Time frame: Day 28

  4. Change from baseline values over time in systolic blood pressure

    Time frame: Day 28

  5. Change from baseline values over time in liver function tests assessed by Comprehensive Metabolic Panel (CMP)

    Time frame: Day 28

  6. Change from baseline values over time of hemoglobin

    Time frame: Day 28

  7. Change from baseline values over time in white blood count

    Time frame: Day 28

  8. Change from baseline values over time in platelets

    Time frame: Day 28

  9. Change from baseline values over time in kidney function assessed by CMP

    Time frame: Day 28

Secondary outcomes

  1. Steady state area under the curve (AUC (0-24)) of eravacycline

    Time frame: Dose cycle 4

  2. Steady state maximum concentration (Cmax) of eravacycline

    Time frame: Dose cycle 4

07

Study locations

5 of 5 sites recruiting
  • UCLA Ronald Reagan University of California Los Angeles Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • Children's Hospital of Orange County
    Orange, California 92868, United States
    Recruiting
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
  • Children's Hospital of LSU Health Sciences Center Shreveport
    Shreveport, Louisiana 71101, United States
    Recruiting
  • West Virginia University Medicine Children's Hospital
    Morgantown, West Virginia 26506, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data requests may be submitted starting 6 months after primary article publication and the data will be made accessible for up to 24 months; extensions may be considered on a case-by-case basis

Access criteria: Subject to certain criteria, conditions, and exceptions and upon completion of the review and approval of the Research Proposal and Statistical Analysis Plan, Qualified Researchers engaging in independent scientific research can be provided de-identified IPD following the execution of a Data Sharing Agreement

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Feb 2029, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2025
First posted
Jan 27, 2025
StartActual
May 22, 2025
Primary completionEst.
Feb 17, 2029
CompletionEst.
Mar 19, 2029
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06794541
Lead sponsor
Tetraphase Pharmaceuticals, Inc
Collaborators
Innoviva Specialty Therapeutics
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
May 22, 2025
Primary completion
Feb 17, 2029 (estimated)
Completion
Mar 19, 2029 (estimated)
Last update
May 5, 2026

Study contacts

ISTX Clinical Trials
Contact
clinicaltrials@istx.com
617-715-3600

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion